Abstract

ObjectiveLong-term survival of patients who undergo surgical resection of isolated adrenal metastasis instead of nonsurgical treatment has shown higher values than those described for stage IVA. The primary endpoint was to evaluate overall survival (OS) of patients with single adrenal metastasis from non-small cell lung cancer (NSCLC), who underwent surgical treatment. The secondary endpoint was to evaluate and compare the OS and disease-free survival (DFS) according to: pathological lung tumour size, histology, lymph node involvement, type of metastasis at the time of diagnosis and laterality of the metastasis according to the primary lung tumour.MethodsFrom August 2007 to March 2020, 13 patients with isolated adrenal gland metastasis were identified. We performed a descriptive observational study including patients with diagnosed single adrenal gland metastasis of resectable primary lung cancer and no history of other malignant disease. Clinical data obtained included patient demographics, metastases characteristics, laterality of the metastasis, time between surgeries, length of follow-up, survival status, pathological lung tumour size, histology and lymph node involvement. The variables analysed were OS and DFS.ResultsMedian global OS was 31.9 months (interquartile range (IQR), 19.1–51.4). The 2- and 5-year OS estimated was 54% (95% CI: 29.5%–77.4%) and 36% (95% CI: 13.4%–68.1%), respectively. In patients with NSCLC without mediastinal lymph node involvement, we obtain a median OS of 40 months (IQR, 27.4–51.4) and a 2- and 5-year OS estimated of 75% (95% CI: 43.2%–92.2%) and 50% (95% CI: 18.7%–81.2%), respectively. Recurrence was detected in five patients with a median DFS of 11.9 months (IQR, 6–34.2).ConclusionThe resection of the adrenal metastasis should be considered if the primary lung cancer is resectable. Presence of mediastinal lymph node involvement should be ruled out through invasive staging of the mediastinum before performing adrenal and lung surgery. Proper selection of patients who would benefit from surgery is essential to obtain better survival results.

Highlights

  • The adrenal glands are a usual metastatic site of non-small cell lung cancer (NSCLC), even though single extra thoracic metastasis in a single organ is uncommon [1]

  • We report our surgical treatment experience for isolated adrenal metastasis from resectable primary lung cancer

  • If we exclude patients with mediastinal lymph node involvement and with large cell neuroendocrine carcinoma (LCNEC), we obtain a median overall survival (OS) of 40 months (IQR, 27.4–51.4) and a 2- and 5-year OS estimated of 75% and 50%, respectively (Figure 2)

Read more

Summary

Introduction

The adrenal glands are a usual metastatic site of non-small cell lung cancer (NSCLC), even though single extra thoracic metastasis in a single organ is uncommon [1]. Reported incidence of isolated adrenal metastasis from NSCLC is 1.6%–3.5% [2, 3]. Management of NSCLC metastasis is still debated, long-term survival of patients who undergo surgical resection of isolated adrenal metastasis instead of nonsurgical treatment has shown a higher average 2- and 5-year survival than the one described by AJCC. We report our surgical treatment experience for isolated adrenal metastasis from resectable primary lung cancer. The primary endpoint was to evaluate OS of patients with single adrenal metastasis from NSCLC, who underwent surgical treatment. The secondary endpoint was to evaluate and compare the OS and disease-free survival (DFS) according to: pathological lung tumour size (pT), histology, lymph node involvement, metastasis characteristics at the time of diagnosis (synchronous versus metachronous) and laterality of the metastasis according to the primary lung tumour

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.